Authors: Zhang Y, Chen X, Wang D, Zhou X, Wang Y, Zhang G, Liu X.
DOI: 10.3389/fonc.2025.1680921
Abstract Summary
Researchers developed a novel biomarker called the DDR-IF score that identifies extensive-stage small-cell lung cancer patients most likely to benefit from combining PARP inhibitors with immunotherapy. Patients with high DDR-IF scores showed a 42% response rate versus 18% in low scorers. This promising tool integrates genomic instability and immune markers to personalize treatment, though prospective trials are needed for validation.
Why Brain? đź§
Novel biomarker identifies ES-SCLC patients who may benefit from combining PARP inhibitors with immunotherapy, showing 42% vs 18% response rates in high-scoring tumors, offering hope for personalized treatment.
License: CC BY.
The image is AI-generated for illustrative purposes only. Courtesy of Midjourney.
